187 related articles for article (PubMed ID: 22085282)
1. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression.
Kuil J; Buckle T; Oldenburg J; Yuan H; Borowsky AD; Josephson L; van Leeuwen FW
Mol Pharm; 2011 Dec; 8(6):2444-53. PubMed ID: 22085282
[TBL] [Abstract][Full Text] [Related]
2. Peptide-functionalized luminescent iridium complexes for lifetime imaging of CXCR4 expression.
Kuil J; Steunenberg P; Chin PT; Oldenburg J; Jalink K; Velders AH; van Leeuwen FW
Chembiochem; 2011 Aug; 12(12):1897-903. PubMed ID: 21739561
[TBL] [Abstract][Full Text] [Related]
3. Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS.
Buckle T; Kuil J; van den Berg NS; Bunschoten A; Lamb HJ; Yuan H; Josephson L; Jonkers J; Borowsky AD; van Leeuwen FW
PLoS One; 2013; 8(1):e48324. PubMed ID: 23326303
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide.
Kuil J; Buckle T; Yuan H; van den Berg NS; Oishi S; Fujii N; Josephson L; van Leeuwen FW
Bioconjug Chem; 2011 May; 22(5):859-64. PubMed ID: 21480671
[TBL] [Abstract][Full Text] [Related]
5. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.
Sand LGL; Buckle T; van Leeuwen FWB; Corver WE; Kruisselbrink AB; Jochemsen AG; Hogendoorn PCW; Szuhai K
BMC Cancer; 2017 May; 17(1):383. PubMed ID: 28549419
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4.
Oishi S; Masuda R; Evans B; Ueda S; Goto Y; Ohno H; Hirasawa A; Tsujimoto G; Wang Z; Peiper SC; Naito T; Kodama E; Matsuoka M; Fujii N
Chembiochem; 2008 May; 9(7):1154-8. PubMed ID: 18412193
[TBL] [Abstract][Full Text] [Related]
7. Hybrid Imaging Labels: Providing the Link Between Mass Spectrometry-Based Molecular Pathology and Theranostics.
Buckle T; van der Wal S; van Malderen SJ; Müller L; Kuil J; van Unen V; Peters RJ; van Bemmel ME; McDonnell LA; Velders AH; Koning F; Vanhaeke F; van Leeuwen FW
Theranostics; 2017; 7(3):624-633. PubMed ID: 28255355
[TBL] [Abstract][Full Text] [Related]
8. High-resolution imaging and single-cell analysis via laser ablation-inductively coupled plasma-mass spectrometry for the determination of membranous receptor expression levels in breast cancer cell lines using receptor-specific hybrid tracers.
Van Acker T; Buckle T; Van Malderen SJM; van Willigen DM; van Unen V; van Leeuwen FWB; Vanhaecke F
Anal Chim Acta; 2019 Oct; 1074():43-53. PubMed ID: 31159938
[TBL] [Abstract][Full Text] [Related]
9. Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery.
Ziarek JJ; Getschman AE; Butler SJ; Taleski D; Stephens B; Kufareva I; Handel TM; Payne RJ; Volkman BF
ACS Chem Biol; 2013 Sep; 8(9):1955-63. PubMed ID: 23802178
[TBL] [Abstract][Full Text] [Related]
10. Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions.
Wang J; He L; Combs CA; Roderiquez G; Norcross MA
Mol Cancer Ther; 2006 Oct; 5(10):2474-83. PubMed ID: 17041091
[TBL] [Abstract][Full Text] [Related]
11. A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.
Choi WT; Kumar S; Madani N; Han X; Tian S; Dong CZ; Liu D; Duggineni S; Yuan J; Sodroski JG; Huang Z; An J
Biochemistry; 2012 Sep; 51(36):7078-86. PubMed ID: 22897429
[TBL] [Abstract][Full Text] [Related]
12. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors.
Hanaoka H; Mukai T; Tamamura H; Mori T; Ishino S; Ogawa K; Iida Y; Doi R; Fujii N; Saji H
Nucl Med Biol; 2006 May; 33(4):489-94. PubMed ID: 16720240
[TBL] [Abstract][Full Text] [Related]
13. Exploration of labeling by near infrared dyes of the polyproline linker for bivalent-type CXCR4 ligands.
Nomura W; Aikawa H; Taketomi S; Tanabe M; Mizuguchi T; Tamamura H
Bioorg Med Chem; 2015 Nov; 23(21):6967-73. PubMed ID: 26453409
[TBL] [Abstract][Full Text] [Related]
14. Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.
Işbilir A; Möller J; Arimont M; Bobkov V; Perpiñá-Viciano C; Hoffmann C; Inoue A; Heukers R; de Graaf C; Smit MJ; Annibale P; Lohse MJ
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):29144-29154. PubMed ID: 33148803
[TBL] [Abstract][Full Text] [Related]
15. Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-based screening.
Nomura W; Tanabe Y; Tsutsumi H; Tanaka T; Ohba K; Yamamoto N; Tamamura H
Bioconjug Chem; 2008 Sep; 19(9):1917-20. PubMed ID: 18707146
[TBL] [Abstract][Full Text] [Related]
16. Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression.
Zhang XX; Sun Z; Guo J; Wang Z; Wu C; Niu G; Ma Y; Kiesewetter DO; Chen X
Mol Imaging Biol; 2013 Dec; 15(6):758-67. PubMed ID: 23636490
[TBL] [Abstract][Full Text] [Related]
17. Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice.
Cheng Z; Wu Y; Xiong Z; Gambhir SS; Chen X
Bioconjug Chem; 2005; 16(6):1433-41. PubMed ID: 16287239
[TBL] [Abstract][Full Text] [Related]
18. Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4.
Zhu S; Meng Q; Schooley RT; An J; Xu Y; Huang Z
Molecules; 2019 Aug; 24(16):. PubMed ID: 31412600
[TBL] [Abstract][Full Text] [Related]
19. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.
Lesniak WG; Sikorska E; Shallal H; Behnam Azad B; Lisok A; Pullambhatla M; Pomper MG; Nimmagadda S
Mol Pharm; 2015 Mar; 12(3):941-53. PubMed ID: 25590535
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
